cyrilzakka/clinical-trials huggingface dataset:
Health Care Use During the Covid19 Crisis

The project US3R is a general population survey that will measure the magnitude of utilised, postponed and foregone medical care in relation with other health care needs than coronavirus symptoms during the confinement period in Belgium. The study aims to describe the magnitude of unsatisfied health care needs for various types of care. It will also identify the reasons for these postponed and foregone care according to gender, health and socioeconomic status.

Context:

Belgium has put in place confinement measures on March 13th 2020 with the aim to reduce contagion related to Covid19 in the population and manage the number of patients to be treated in the hospital.

However, some weeks after those confinement measures, health care professionals are worry about other patients than Covid19 since they have observed a significantly lower use of emergency services, cancellations of screening appointments, interrupted health care in patients with chronic conditions, disabilities, or mental health disorders.

Objectives: to collect data on used, postponed and foregone medical care related to other health care needs than Covid19 during the confinement period in Belgium; to measure the magnitude of unsatisfied health care needs for various types of care; to identify the reasons explained postponed and foregone care

Methods : the survey is made of about 50 questions collecting self-reported data on health care use and non-use for various types of care along with demographics, socioeconomics and health status characteristics during the confinement period . Data will be analysed with Stata 15 using statistical tests and regression models.

Participants are collected via social media platforms and institutionnal mailing, and Belgian newspapers.

Eligibility Criteria:
Inclusion Criteria:

* living in Belgium
* more than 18

Exclusion Criteria:

* living outside Belgium
* less than 18
Comparison of Videogame Based Dance Training With Agility Ladder Drills on Agility of Volleyball Players

This study will examine the effects of six week dance training, using the Xbox Kinect Just Dance 2014 programme, on the agility scores along with general and hamstring flexibility and extensibility of the hip flexor. The effects of the dance programme will be compared with those of proven agility training techniques (ladder drills).

A randomised clinical trial will be used consisting of 34 (17 in each group) athletes undergoing training. Both groups will undergo one hour of training three times weekly for six weeks, with one group doing dance training (DT) using the Xbox Kinect and the other doing standard training (ST) using traditional ladder drills. Outcomes will be assessed using the Illinois Agility test for agility, sit and reach test for general flexibility, straight leg raise test for hamstring flexibility and the Thomas test for hip flexor extensibility.

Eligibility Criteria:
Inclusion Criteria:

* To be included in the study persons must be playing volleyball at the University of the West Indies at competitive levels and will be required to give written consent to participate in the study.

Exclusion Criteria:

- 1. Anyone who currently has a musculoskeletal injury of the lower limb that prevents them from performing the respective activities.

2. Anyone involved in a dance programme as this will confound the results of the study.
A Multicentric Cohort of Autoimmune Encephalitis

This study aims to establish an autoimmune encephalitis cohort and observe the prognosis of patients with different subtypes and subgroups (e.g. epilepsy subgroup and teratoma subgroup ). Clinical characteristics, biological samples, and imaging data will be collected to discover blood and imaging biomarkers for providing support for the treatment, early warning, and outcome prediction.


Eligibility Criteria:
Inclusion Criteria:

* 1. Gender and age are not limited; 2. Newly diagnosed autoimmune encephalitis according to at least one of the following three criteria:

  1. According to the criteria of Graus et al in 2016, diagnosed as "definite autoimmune limbic encephalitis"
  2. According to the criteria of Graus et al in 2016, diagnosed as "possible autoimmune encephalitis" and typical autoantibodies are detected in serum or cerebrospinal fluid
  3. According to the criteria of Graus et al in 2021, diagnosed as "possible or definite paraneoplastic neurological syndrome" (excluding peripheral nervous system syndrome) 3. The patient or legal representative voluntarily signed the paper informed consent form.

Additional inclusion criteria for patients in the epilepsy subgroup: patients diagnosed with epilepsy secondary to autoimmune encephalitis.

Exclusion Criteria:

* No additional exclusion criteria
Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis

The purpose of this study is to evaluate Halobetasol Propionate (HBP) foam, 0.05% in subjects aged 12 through less than 18 years with plaque psoriasis in order to check the safety, the potential to suppress the adrenal glands and the degree to which the drug is absorbed into the bloodstream.

This is a Phase 4 (for US site only, Phase 2 for non-US sites), open label, multicenter study of halobetasol propionate (HBP) Foam, 0.05% in male and female subjects who are 12 to less than 18 years of age with stable plaque psoriasis. Twenty-four subjects with stable plaque psoriasis on at least 10% of their body surface area (BSA) (excluding the face, scalp, groin, axillae, and other intertriginous areas), who fulfill the inclusion/exclusion criteria will be enrolled at multiple study sites in the US and Europe. All subjects are to have a Cosyntropin Stimulation Test (CST) to assess their (hypothalmic pituitary adrenal) HPA axis response at Visit 1/Screening initiated between 7 and 9 AM. Enrollment into the treatment phase of the study will be timed such that the Screening CST is performed a minimum of 20 days before Visit 2/Baseline. At Visit 2/Baseline, eligible subjects with normal adrenal function will be eligible to participate in the study.

The primary objective of the study is to assess safety, not efficacy. Safety will be determined by assessing the adrenal suppression potential and the PK properties of HBP Foam, 0.05% applied twice daily in male and female subjects who were 12 to less than 18 years of age with stable plaque psoriasis.

Other safety endpoints include plasma levels of HBP. Trough HBP concentrations in plasma on day 8 and 15 will be calculated and summarized. Efficacy will also be noted utilizing the Investigator's Global Assessment (IGA) scale and percent BSA treated and affected with disease to assess and document any changes observed with regard to IGA and percent BSA.

Eligibility Criteria:
Key Inclusion Criteria:

* Subject is male or non-pregnant female and is 12 to less than 18 years of age
* Subject has provided written informed assent and was accompanied by the parent or legal guardian at the time of assent/consent signing
* Subject has a clinical diagnosis of stable plaque psoriasis involving a minimum of 10% Body Surface Area (BSA)
* Subject has an Investigator's Global Assessment (IGA) score of at least three (3 = moderate) at the Baseline Visit

Key Exclusion Criteria:

* Subject has spontaneously improving or rapidly deteriorating plaque psoriasis
* Subject has guttate, pustular, erythrodermic or other non-plaque forms of psoriasis
* Subject has a physical condition which, in the investigator's opinion, might impair evaluation of plaque psoriasis, adrenal axis function or which exposes the subject to an unacceptable risk by study participation
* Subject has had prolonged exposure to natural or artificial sources of ultraviolet radiation
* Subject is pregnant, lactating, or is planning to become pregnant during the study
* Subject is currently enrolled in an investigational drug or device study
Compassionate Use Study of Pergolide in Patients With Parkinson's Disease

This compassionate use study is designed to monitor safety in patients who have been doing well on pergolide therapy, wish to continue treatment, and have not been able to tolerate alternative treatments.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with Parkinson's disease and treated successfully with pergolide in the recent past
* Attempt to taper off pergolide was unsuccessful and patient was unable to change to other forms of therapy for Parkinson's disease
* No evidence of cardiovalvular disease by echocardiogram conducted within 60 days prior

Exclusion Criteria:

* History or current diagnosis of cardiac valvulopathy
* Inability to undergo echocardiograms every 6 months while receiving pergolide
* Hypersensitivity to pergolide or other ergot derivatives
Genomic Basis of Neurodevelopmental and Brain Outcomes in Congenital Heart Disease (CHD Brain and Genes)

Approximately 400 Congenital heart disease patients will participate in the research study which will include one or more research visits for neurodevelopmental testing, brain MRI, and collection of medical history including previously collected genetic sequencing results. The investigators will explore the association between genetic variants, neurodevelopmental deficits, and brain MRI endophenotype. Analyses will compare groups with and without deleterious de novo mutations.


Eligibility Criteria:
Inclusion Criteria:

1. Subjects in whom whole exome sequencing or whole genome sequencing has already been performed, either during the CHD GENES study or, for new centers (Utah or USCF/Stanford), after trios in existing biobanks undergo analysis by whole exome sequencing or whole genome sequencing during the Pediatric Cardiac Genomic Consortium 2 grant cycle
2. Presence of deleterious mutations (damaging de novo mutations or stringently defined deleterious missense mutations) identified on sequencing (Cases) OR absence of such known deleterious mutations (Controls)
3. Males or females, age ≥8 years
4. Diagnosis of congenital heart disease
5. Informed consent obtained

Exclusion Criteria:

1. History of cardiac transplant
2. A cardiac surgical procedure within 6 months of enrollment
3. Known clinical genetic syndrome, characterized as a monogenic condition with an identified gene associated with abnormalities of the brain structure or function, structural heart disease, and potentially other associated features.
4. Presence of CNV known to be clinically pathogenic. Variants will be classified as pathogenic using accepted types of variant evidence (e.g., population data, computational data, functional data, segregation data) as detailed in the American College of Medical Genetics and Genomics " Standards and Guidelines for the interpretation of sequence variants" (Richards et al, GIM 2015).
5. Overwhelming acquired brain injury, such as a major stroke or severe ischemic injury, that would overshadow the effect of a genetic mutation on outcome in the opinion of the center investigator
6. Lack of reading fluency in English or Spanish
Influence of Vitamin D on Inflammatory Bowel Disease Remission

Vitamin D has been shown to influence a multitude of systems. We intend to see whether different types of Vitamin D supplements have an effect on inflammatory bowel disease.


Eligibility Criteria:
Inclusion Criteria:

* Mild to moderate inflammatory bowel disease

Exclusion Criteria:

* Hypersensitivity to milk products
Brachial Artery Blood Pressure Measurement Training

The research is a pre-post-test observation study without a control group, aiming to determine the effect of the training given to nurses on the knowledge and practices of brachial artery blood pressure measurement.

The nurses who were informed about the study and agreed to participate in the study will be followed by two observers at the same time and filled in the "Blood Pressure Measurement Observation Form". Nurses will not be informed by whom and when they will be observed. Each observer will observe each nurse three times (1st observation). After the first observation is over, the "Blood Pressure Knowledge Test" will be applied to the nurses (Pre-test). Then, the training program prepared by the researcher will be uploaded to the hospital automation system and nurses will be asked to follow it. In addition, nurses will be able to log in to the training module and watch the video again and again whenever they want. Nurses will be given a two-week period to follow the training module. At the end of two weeks, the nurses will fill out the "Blood Pressure Information Test" again (2nd test). The "Blood Pressure Measurement Observation Form" will be filled in by the researcher during the blood pressure measurement of the nurses again in the form of the final follow-up (2nd observation).

Eligibility Criteria:
Inclusion Criteria:

* Volunteering to participate in the study
* Measurement of blood pressure from the brachial artery with a sphygmomanometer
* Caring for adult patients

Exclusion Criteria:

* Using only digital sphygmomanometer in the clinic
* Caring for pediatric patients
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease

The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.

The study will use structural and functional MRIs, daTscans, fluorodeoxyglucose (FDG) PET scans, Amyvid PET scans, polysomnographs, neuropsychological testing, cerebrospinal fluid in willing participants to distinguish between a diagnosis of Alzheimer's disease, Lewy Body dementia, and Parkinson's Disease. All subjects will have a clinical evaluation, physical examination including vital signs and orthostatic blood pressures and pulses, neurological examination including UPDRS evaluation, genetic blood sample collection, neuropsychological testing, polysomnogram, and neuroimaging. The study partner will also be interviewed for completion of all of the behavioral and functional measures.

Eligibility Criteria:
Inclusion Criteria:

* Subjects must meet the standard clinical criteria of the syndromes of interest
* All subjects must have enough cognitive abilities to complete study procedures, which will be operationally defined as having a Mini Mental State Examination (MMSE) score greater or equal to 10.
* Subjects must be on stable cognitive and psychoactive medication regimen for the preceding four weeks of enrollment.
* Subjects must have a responsible study partner that either lives with them or is in regular contact with them at least 4 out of 7 days per week.
* Subjects must have visual and auditory acuity adequate for testing.

Exclusion Criteria:

* Any other condition (other than the primary diagnosis), which in the opinion of the investigators might contribute to the syndrome of dementia or complicate its assessment.
* active medical disorder that could preclude participation in this protocol
* Women who are pregnant or are breast feeding
* severe renal impairment as defined by glomerular filtration rate (GFR) less than 30 (may have increased radiation exposure with the DaTscan).
* Subjects in whom English is not the 1st language
* Subjects with educational level less than 12 years
* Subjects who have ever participated in an experimental study with an amyloid targeting agent unless it can be documented that the subject received only placebo during the course of the trial.
Lock sOlutiOnS for Epicutaneo-caval Catheters in Neonates: a "LOOSEN" Pilot Study

Epicutaneo-caval catheters (ECCs) are widely used in neonatal intensive care units (NICUs). They are small catheters inserted via superficial veins of the limbs or scalp using direct vein visualization The pathogenic microorganisms colonized inside catheters can easily form a bacterial biofilm and eventually spread with blood flow which causes bloodstream infection. Many authors have studied the antibiotic-lock therapy (ALT) in which a high-dose antibiotic solution is dripped and maintained in the catheter cavity for a certain period and can dissolve the biofilm formed on the wall to reduce the colonization of the bacteria and kill the embedded bacteria.The aim of the study is to evaluate the patency of the Epicutaneo-caval catheter after its closure for 1 hour.


Eligibility Criteria:
Inclusion Criteria:

All the Epicutaneo-caval catheter that need to be removed electively will be included in the study -

Exclusion Criteria:

All the Epicutaneo-caval catheters removed not electively but for infectious or mechanical complications will be excluded from the study.

-
Simulation-based Arthroscopic Surgery Study

The purpose of this study is to determine whether simulation training improves the performance during arthroscopic surgery ('keyhole' surgery into a joint).

This single blinded randomised controlled study of junior orthopaedic trainees aims to assess whether the addition of simulation training improves arthroscopic technical skills performance of junior orthopaedic trainees during knee arthroscopy in the operating theatre compared to their usual clinical training programme. This will be assessed using objective motion analysis parameters recorded from wireless elbow-mounted motion sensors during surgery.

Eligibility Criteria:
Inclusion Criteria:

* Participant is willing and able to give informed consent for participation in the study.
* Healthy adults, Male or Female, aged 18 years or above.
* Enrolled in Health Education Thames Valley/Oxford Deanery Training Programme in junior surgical training posts

Exclusion Criteria:

* Unwilling or unable to provide informed consent
* Previously completed higher surgical training programme
Exercise and Oxaliplatin-induced Peripheral Neuropathy

This single group study was conducted to test the feasibility and acceptability of implementing an exercise intervention during oxaliplatin infusion across three months of oxalipatin-based chemotherapy in patients with gastrointestinal malignancies.10 patients were enrolled onto this study and validated questionnaires were used to evaluate the feasibility and acceptability of the intervention and collect patient-reported outcomes over the course of study enrollment.

The proposed study is a single arm study to evaluate the feasibility and acceptability of having patients exercise while receiving oxaliplatin infusions in the infusion center. The study will enroll patients receiving oxaliplatin-containing chemotherapy for gastrointestinal cancersor for cancer of unknown primary.

Patients will be provided with a wrist heart rate monitors to be used during the infusions. They will wear the heart monitors during the entirety of the oxaliplatin chemotherapy infusion. Patients will be asked to engage in aerobic exercise using a pedal machine to move their arms and legs while in a seated position. Patients will be asked to exercise for a total of 30 minutes, which will be divided into three, ten minute bouts of exercise, spaced out in 30 minute blocks of time.

The comprehensive surveys including EORTC-QLC-CIPN20 and PROMIS-29 QOL will be completed at baseline, \~6-8 weeks into treatment, and at \~12-14 weeks after treatment initiation. The feasibility and acceptability instruments will be administered \~6-8 weeks into treatment.

Eligibility Criteria:
Inclusion Criteria:

1. Receiving care at Dartmouth-Hitchcock Medical Center in Lebanon, NH
2. Age \>18 years
3. Eastern Cooperative Oncology Group Status 0 to 2;
4. Diagnosed gastrointestinal cancer of any stage
5. Scheduled to receive at least 4 cycles of oxaliplatin
6. Complete the International Physical Activity Questionnaire score equal to or greater than 99 MET minutes/week (equivalent to \~30 minutes of walking)
7. Have mediport access prior to enrollment in the study

Exclusion Criteria:

1. Exercise- or mobility-limiting cardiovascular, pulmonary, musculoskeletal, or psychological disease, based on the EMR (electronic medical record) past medical history and/or based on consultation with the medical oncologist;
2. Scheduled major surgery during the study time period;
3. Pre-existing peripheral neuropathy prior to chemotherapy;
4. Patient with a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator;
5. Prior history of treatment with oxaliplatin, docetaxel, or paclitaxel
6. Pregnant women;
7. Prisoners;
8. Inability to read or speak English/unable to consent;
9. Prognosis of less than six months
Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and During Treatment or Thereafter in Acute Leukemia

The objective of this study is to evaluate the prognostic factors of acute leukemia patients and to invent the molecular genetic test for sensitive detection of minimal residual disease, and thereby this study would contribute to plan the risk adapted treatment. Patients will have samples of blood and/or bone marrow collected during diagnosis process, treatment and/or thereafter


Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with acute leukemia in Severance Hospital.
* Both genders of 16 Years and older
* sign a written informed consent document

Exclusion Criteria:

* No comprehension or willingness to sign a written informed consent document.
Goldmann Applanation Tonometry, Dynamic Contour Tonometry, and Corvis ST Tonometer

The study is investigating Intra ocular pressure (IOP) by Goldmann Applanation Tonometry, Dynamic Contour Tonometry, and the Corvis ST tonometer.

The aim of the study is to approach the "true" Intra ocular pressure (IOP) by correlating the difference between IOP by Goldmann Applanation Tonometry to the IOP by Dynamic Contour Tonometry to the biomechanical parameters of the cornea measured by Corvis ST. Therefore the investigators gain new findings about the influence of the biomechanical corneal parameters on the IOP. In order to do so the investigators want to examine 50 Glaucoma eyes and 50 non-Glaucoma Eyes with Goldmann Applanation Tonometry, Dynamic Contour Tonometry, and Corvis ST.

Eligibility Criteria:
Inclusion Criteria for the glaucoma group:

* diagnosis of glaucoma
* 18 years old or older with no upper limit

Exclusion Criteria for the glaucoma group:

* IOP lowering surgery within the last 3 weeks
* any corneal surgery in the past
* bad fixation
* insufficient measurement quality with any of the study devices

Inclusion Criteria for the healthy control group:

* no diagnosis of glaucoma
* 18 years old or older with no upper limit

Exclusion Criteria for the healthy control group:

* any diagnosis of glaucoma
* IOP lowering surgery within the last 3 weeks
* any corneal surgery in the past
* bad fixation
* insufficient measurement quality with any of the study devices